White Blood Cell Profiles in Long-Term Captive and Recently Captured Eastern Tiger Salamanders (Ambystoma tigrinum)

Appropriate use of myeloid growth factors may reduce the risk of neutropenic complications including febrile neutropenia (FN) in patients receiving cancer chemotherapy. The recently updated American Society of Clinical Oncology (ASCO) Guidelines on the Use of the White Blood Cell Growth Factors recommends routine prophylaxis with these agents starting in the first cycle when the risk of FN is 20% or greater. However, the risks for neutropenic complications and the risk of serious adverse consequences from FN vary considerably with different chemotherapy regimens as well as other disease-, treatment-, and patient-specific risk factors. Considerably more information is now available on the major risk factors for FN. Multivariable risk models combining factors look promising but require further validation. Most clinical studies of myeloid growth factor prophylaxis assessed relative risk (RR) of FN but were not powered to evaluate the effect of prophylaxis on disease-free or overall survival. Accumulating evidence suggests, however, that the appropriate use of these agents in selected patients may improve both short-term and long-term survival by reducing the immediate risk of mortality accompanying patients with high-risk disease developing FN as well as improving disease-free and overall survival by enabling the delivery of full dose intensity chemotherapy and reducing the risk of disease recurrence in patients treated with curative intent. Further studies to evaluate risk factors and models for FN are needed to guide clinical and shared decision making for the optimal personalized use of these agents and offer patients at increased risk the best chance of long-term disease control.

Download Full-text

A white blood cell control of long-term stability

Clinica Chimica Acta ◽

10.1016/0009-8981(83)90153-5 ◽

1983 ◽

Vol 129 (1) ◽

pp. 79-83 ◽

Cited By ~ 4

Author(s):

A.J.P.F. Lombarts ◽

B. Leijnse

Keyword(s):

Blood Cell ◽

White Blood Cell ◽

Cell Control ◽

Term Stability ◽

Long Term Stability

Download Full-text

White Blood Cell Subtypes Are Associated with a Greater Long-Term Risk of Death after Acute Myocardial Infarction

Texas Heart Institute Journal ◽

10.14503/thij-16-5768 ◽

2017 ◽

Vol 44 (3) ◽

pp. 176-188 ◽

Cited By ~ 8

Author(s):

Arthur Shiyovich ◽

Harel Gilutz ◽

Ygal Plakht

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Blood Cell ◽

White Blood Cell ◽

Neutrophil To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Cell Counts ◽

Blood Cell Counts ◽

White Blood Cell Counts

We evaluated the association between white blood cell counts and long-term mortality rates in 2,129 patients (mean age, 65.3 ± 13.5 yr; 69% men) who had survived acute myocardial infarction. We obtained white blood cell counts and differential counts of white blood cell subtypes within the first 72 hours of hospital admission. The primary outcome was all-cause death at 1, 5, and 10 years after acute myocardial infarction. In regard to death in the long term, we found significant negative linear associations (lymphocytes), positive linear associations (neutrophils and the neutrophil-to-lymphocyte ratio), and nonlinear U-shaped associations (basophils, eosinophils, monocytes, and total white blood cell count). After multivariate adjustment for the Soroka Acute Myocardial Infarction risk score, lymphocytes (strongest association), neutrophil-to-lymphocyte ratio, and eosinophils were independently associated with death for up to 10 years after hospital discharge. The independent associations weakened over time. We conclude that lymphocyte count, neutrophil-to-lymphocyte ratio, and eosinophil count are independently and incrementally associated with death in the long term after acute myocardial infarction.

Download Full-text